Haematopoietic stem cell therapy - Asterias Biotherapeutics

Drug Profile

Haematopoietic stem cell therapy - Asterias Biotherapeutics

Alternative Names: Haematological disorders-hESC therapy - BioTime; Haematological disorders-hESC therapy - Geron

Latest Information Update: 01 Apr 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Geron Corporation
  • Developer Asterias Biotherapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bone marrow disorders; Haematological disorders

Most Recent Events

  • 01 Oct 2013 Preclinical trials in Bone marrow disorders in USA (unspecified route)
  • 01 Oct 2013 Preclinical trials in Haematological disorders in USA (unspecified route)
  • 01 Oct 2013 Asterias Biotherapeutics completes acquisition of the human embryonic stem cell programmes of Geron Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top